| Date | Title | Description |
| 10.07.2025 | Attorneys Steven Hill and David Ludwig Named to List of World's Leading Patent Litigators | (l-r) Steven Hill, David Ludwig
Two attorneys at the U.S.-based law firm Hill, Kertscher & Wharton, LLP were recently named to the Intellectual Asset Management (IAM) Patent 1000: The World's Leading Practitioners for their work on beha... |
| 09.07.2025 | Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses | Hims & Hers Health announced plans to expand to Canada in 2026.
Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection.
Novo Nordisk will lose its patent protection on its branded semagluti... |
| 21.05.2025 | Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars | MEDIA RELEASE
Pyzchiva® first ustekinumab biosimilar in Europe commercially available in pre-filled pen (autoinjector), offering improved self-administration experience for better treatment adherence and quality of life [1-10]
Autoinjector ... |
| 29.04.2025 | Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar | Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations
Henlius to receive $31 million upfront, and up to $270 million in milestones
SHANGHAI, April 29, 2025 /PRNew... |
| 29.04.2025 | Перечень жизненно важных лекарств не резиновый | - |
| 14.04.2025 | Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US | Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling inflammatory diseases
Despite FDA approval ne... |
| 10.04.2025 | Helio Fujita joins Mars as Global People & Organization VP for Petcare business | Mars announces Helio Fujita as Global P&O VP for Mars Petcare, Fujita will join the Mars Petcare Leadership Team and global People & Organization Team
Recognized HR leader with over 25 years' experience in HR joins from Fresenius Ka... |
| 01.04.2025 | Trump’s tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks | - |
| 31.03.2025 | Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility | MEDIA RELEASE
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further strengthen Sandoz balance sheet and liquidityNew facility rep... |
| 25.03.2025 | OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer | BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced th... |
| 14.03.2025 | Tariff Turbulence: The Ripple Effect on U.S. Businesses | In the whirlwind of global trade, tariffs are the storm clouds gathering on the horizon. President Donald Trump’s recent threats of $1.4 trillion in tariffs have sent shockwaves through corporate America. Companies are scrambling to adapt, ... |
| 13.03.2025 | Donald Trump’s $1.4 trillion tariff threats scramble business plans, US companies form task-forces to tackle impact | Ozempic-maker Novo Nordisk A/S is planning to make more of its medicines for the US market in the country; Boeing Co. risks a gummed up supply chain and higher aircraft costs it may not be able to pass on; Chinese online retailer Shein Grou... |
| 12.03.2025 | Выпускайте субстанцию: фарма ищет лучшую версию себя | - |
| 02.03.2025 | The Shifting Sands of Shareholder Stakes: A Look at Recent Market Movements | In the world of finance, change is the only constant. Recently, two significant transactions have caught the eye of investors and analysts alike. The Sandoz family’s decision to sell a $2.9 billion stake in Novartis and EQT’s public offerin... |
| 26.02.2025 | Sandoz Family to Sell $2.9 Billion Stake in Novartis | (Bloomberg) -- Novartis AG’s Sandoz family is poised to sell a roughly 1.2% stake in the Swiss pharmaceutical group.
The Sandoz Family Foundation, through the vehicle Emasan AG, is offering 26.5 million shares via an accelerated placement, ... |
| 14.01.2025 | Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference | MEDIA RELEASE Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilarsLeading in home market Europe, which represents half of total sales... |
| 14.01.2025 | Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference | MEDIA RELEASE Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilars Leading in home market Europe, which represents half of total sale... |
| 17.12.2024 | Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation | Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
Sandoz takes further steps to resolve legacy US generic drug antitrust class action litigation Sandoz US has entered into a settlement agreement with the class of end ... |
| 30.10.2024 | Sandoz reports third-quarter and nine-month 2024 sales | Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
MEDIA RELEASE
Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launches
Generics growth acceleration driven by ... |
| 07.10.2024 | Sandoz Canada achieves carbon neutral certification for its commercial operations | Sandoz Canada head office and sales force operations certified carbon neutral by LCL Engineering, Environment & Sustainable DevelopmentCO2 emissions offset through the purchase of carbon credits from environmental organizationsInitiativ... |
| 24.09.2024 | Temasek's Bold Leap into Climate Action: A $100 Million Commitment | In a world grappling with climate change, Temasek Holdings has stepped up. The Singaporean investment firm recently announced a commitment of S$100 million (approximately US$77.5 million) to support climate action initiatives. This move, re... |
| 20.09.2024 | Marking 11 Years of Culinary Distinction: The Big F Awards Recognizes Delhi-NCR's Top Talent in 2024 | Delhi NCR, India
The prestigious 11th edition of the Big F Awards, known for its integrity concluded with grandeur and excitement, honoring the pinnacle of excellence in the food and beverage industry. Hosted at The Westin on 18th September... |
| 12.09.2024 | Qualifyze: Life Sciences Supplier Risk Management Company Raises $54 Million (Series B) | Qualifyze, a supplier risk management company in the Life Sciences industry, announced $54 million in Series B funding from Insight Partners. Existing investors HV Capital, HarbourVest Partners, H14, and Cherry Ventures also participated.
W... |
| 10.09.2024 | Qualifyze Raises $54M in Series B Funding | Qualifyze, a Frankfurt, Germany-based company which specializes in supply chain risk management in the Life Sciences industry, raised $54M in Series B funding.
The round was led by Insight Partners, with participation from existing investor... |
| 08.08.2024 | Sandoz reports second-quarter sales and half-year 2024 results | Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
MEDIA RELEASE Strong double-digit growth in biosimilars of 29% from existing portfolio and recent launches Second-quarter net sales[1] of USD 2.6 billion, up 9% in con... |
| 25.07.2024 | Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases | Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Launch across Europe, starting today, strengthens well-establi... |
| 25.07.2024 | Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases | Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Launch across Europe, starting today, strengthens well-establi... |
| 10.07.2024 | Direct Purchaser Plaintiffs Announce an Additional Settlement in In Re Generic Pharmaceutical Pricing Antitrust Litigation | PHILADELPHIA, July 10, 2024 /PRNewswire/ --
NastLaw LLC announces: If you purchased certain named generic pharmaceutical drugs directly from certain pharmaceutical manufacturers from May 1, 2009 through December 31, 2019, your rights may be... |
| 03.06.2024 | Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi® (bevacizumab), a Biosimilar Referencing Avastin® | CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing Avzivi® to the reference product Avastin®
GUANGZHOU, China, June 3, 2024 /PRNewswire/ -- Bio-Thera Solutions Inc. (688177:SH), a commerc... |
| 10.05.2024 | Axios Event: Drug shortages problem will require policy solutions to fix low prices, shift market dynamics | figcaption>span]:font-sans">
WASHINGTON, D.C. – Ongoing shortages of generic drugs have plagued the American health care system in recent years as a variety of complex factors around pricing, increased demand and supply chain iss... |
| 03.05.2024 | Patients on hunt for diabetes, obesity and weight-loss drugs | - |
| 15.03.2024 | Biocon slips 5% on plan to sell branded formulation biz to Eris | Shares of Biocon slipped 5 per cent to Rs 254.15 on the BSE in Friday’s intra-day trade as the company’s unit Biocon Biologics will sell its Indian branded formulations businesses to Eris Lifesciences in a deal worth Rs 1,242 crore ($150 mi... |
| 13.03.2024 | Sandoz reports fourth quarter 2023 sales and full-year 2023 results | - |
| 13.03.2024 | Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update | – Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI® net sales of $52.4 million in the fourth quarter and... |
| 09.03.2024 | Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology (AAD) Annual Meeting | Interchangeability study for HADLIMA (adalimumab-bwwd) was conducted in accordance with the FDA’s Guidance for Industry; primary pharmacokinetics (PK) endpoints as well as efficacy, safety and immunogenicity profiles were comparable between... |
| 05.03.2024 | Sandoz receives FDA approval for first and only denosumab biosimilars | - |
| 05.03.2024 | Sandoz announces nominations to the Board of Directors and leadership change | - |
| 05.03.2024 | FDA Approves Sandoz Biosimilars for Two Blockbuster Amgen Bone Drugs | A blockbuster Amgen antibody that treats bone conditions is set to face its first biosimilar competition. The FDA on Tuesday approved two Sandoz drugs as interchangeable with and approved for all uses of the Amgen products.
The Amgen antibo... |
| 29.02.2024 | Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs | Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE
Sandoz US to pay USD 265 million in exchange for full release of all claims by the class
Resolves all federal antitrust damages for direct purchaser clas... |
| 20.02.2023 | Novartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors | Gilbert Ghostine, CEO of the Swiss multi-national fragrances business Firmenich appointed Chairman-Designate of the future Sandoz Board Mr Ghostine to begin role as Sandoz Chairman following the spin-off from Novartis
Basel, February 20, 20... |
| 19.09.2022 | Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial | ROSALIA study met primary endpoints, confirming proposed biosimilar denosumab matches reference product in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in postmenopausal women with osteoporosis
Osteoporos... |
| 25.08.2022 | Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off | Ad hoc announcement pursuant to Art. 53 LR Sandoz strategic review concludes that a separation of Sandoz by way of a 100% spin-off is in the best interest of shareholders, creating the #1 European generics company and a global leader in bio... |
| 25.07.2022 | Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA | Submission of proposed biosimilar supported by comprehensive package; aims to expand treatment access for people with multiple sclerosis in US and EU
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease that can d... |
| 21.07.2022 | Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF) | Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study
Proposed Hyrimoz® HCF would help expand access to medicine for patients with chronic immune-mediated inflammatory diseases
Sa... |
| 17.06.2022 | Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA | Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study
Adalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced yet familiar experience for patients
Submi... |
| 27.05.2022 | Sandoz appoints new Board representative to global AMR Industry Alliance | Dr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to represent Sandoz as Board member of AMR Industry Alliance (AMRIA)
The Alliance brings together about 100 life science companies / associations in search ... |
| 14.04.2022 | Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio | Brimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1
Ocular hypertension affects over 5% of all adults2; the eye does not properly drain fluid, causing eye pre... |
| 06.04.2022 | Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR) | Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025
Both parties strengthening focus on antibiotic stewardship and planni... |
| 14.03.2022 | Alzheimer’s group amps public pressure with ad campaign as Medicare decision looms | A new seven-figure ad campaign takes aim – again – at Medicare’s pending coverage decision on Alzheimer’s disease anti-amyloid drugs.
UsAgainstAlzheimer’s launched the $1 million-plus national effort Sunday, including a TV ad that ran acros... |
| 14.03.2022 | GreenLight licenses mRNA shingles vaccine to Serum Institute following a $10M investment | GreenLight Biosciences has come a long way from trying to shake up the pesticides market.
The Medford, MA biotech signed a deal Monday with the Serum Institute of India to design three mRNA products, including a shingles vaccine, for develo... |
| 14.03.2022 | GMP-in-a-box company with Bob Nelsen backing lands $167M to develop its own cancer drugs | For the fourth time in as many weeks, a company focused on portable drug manufacturing is making noise.
This time, Nutcracker Therapeutics has brought in $167 million in a Series C round led by ARCH Venture Partners. The company will use th... |
| 14.03.2022 | As Sandoz waits for Novartis to determine its fate, the generics player buys out a respiratory device company | While Novartis chief Vas Narasimhan mulls whether or not the pharma will sell off Sandoz, the giant generics drug subsidiary is still trucking along like business as usual.
On Monday, the company acquired Coalesce Product Development Limite... |
| 14.03.2022 | Alzheimer’s group amps public pressure with ad campaign as Medicare decision looms | AstraZeneca will have to sit outside the ring of a hotly contested respiratory fight for now.
Despite what the pharma giant described as positive Phase III data, the FDA has rejected its sBLA for Fasenra in patients with inadequately contro... |
| 14.03.2022 | Sandoz targets growth opportunities in respiratory and complex generics through acquisition of respiratory device company Coalesce | Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics
Respiratory diseases are leading cause of death and disability and impose hug... |
| 18.02.2022 | Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine | Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4
Cost savings from Lenalidomide Sandoz can expand treatment options for patients with haemato-oncology conditions1,2
... |
| 10.01.2022 | Novartis : COVID-19 news feed | Find the latest coronavirus (COVID-19) news from Novartis regarding clinical trials, collaborations, aid contributions, and more.
Jan 10, 2022
Jan 10, 2022 Novartis and Molecular Partners report positive topline data from Phase 2 study for ... |
| 05.01.2022 | Teva and Novartis’ Sandoz launch Narcan generics on same day, brand marketer Emergent remains in play | Teva and Novartis’ Sandoz recently launched generic versions of Narcan on the same day, but it likely wasn’t a coincidence. Both first-to-market generics for Narcan, an opioid overdose rescue nasal spray, are FDA approve... |
| 22.12.2021 | Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA | Submission is supported by comprehensive package of analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc.
Breast cancer is one of most common types of cancer in women, accounting for over 35... |
| 20.12.2021 | Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA | Biologics License Application (BLA) is supported by analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc.
Trastuzumab is monoclonal antibody used to treat human epidermal growth factor recep... |
| 21.10.2021 | Novartis : COVID-19 news feed | Find the latest coronavirus (COVID-19) news from Novartis regarding clinical trials, collaborations, aid contributions, and more.
Oct 21, 2021
Novartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-... |
| 11.10.2021 | Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics | Sandoz gains rights to three established brands sold in more than 100 markets
Transaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading position in cephalosporins
Acquisition conf... |
| 04.10.2021 | Sandoz Canada launches PrSandoz® Dimethyl Fumarate Delayed-Release Capsules, a generic equivalent to PrTecfidera* | Dimethyl Fumarate DR Capsules is indicated as monotherapy for the treatment of relapsing remitting multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the progression of disability.
PrSandoz® Dimethyl Fuma... |
| 16.07.2021 | Sandoz launches first generic high dose intravenous iron, Ferumoxytol Injection, to treat US patients with iron deficiency anemia | |
| 17.05.2021 | US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case | Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients
Sandoz is disappointed US patients affected by chronic autoimmune and inflammatory disease... |
| 16.02.2021 | Sandoz Canada completes its 5th biosimilar launch with new biosimilar Hyrimoz® (adalimumab) | Hyrimoz® for use in nine indications covered by the reference medicine* in the fields of rheumatology, gastroenterology and dermatology.
New Sandoz biosimilar to broaden access to critical adalimumab biologic treatment and free up resources... |
| 11.02.2021 | Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics | Sandoz to acquire three established brands sold in more than 100 markets
Acquisition, including leading global brand Zinnat®, confirms Sandoz commitment to antibiotics, following plans to expand its integrated manufacturing site in KundlTra... |
| 28.01.2021 | Sandoz launches generic Icatibant in US for rare disease hereditary angioedema, strategically enhancing injectables portfolio | |
| 05.04.2020 | In FDA authorization of malaria drugs for Covid-19, some see politics at play | Buildings 1 and 2 of the FDA campus
Last weekend, the Food and Drug Administration granted an emergency use authorization for hydroxychloroquine and chloroquine to treat Covid-19, despite a paucity of data to support their use in the diseas... |
| 06.03.2020 | Five years on, biosimilars need support from all health care players | Today marks a milestone for the U.S. biosimilar market: the FDA approved our first biosimilar, Sandoz’s Zarxio, five years ago, on March 6, 2015.
The biosimilar category holds incredible promise, and the market for these products is on an u... |
| 23.01.2020 | The CEO of a company that makes prescription apps to treat diseases asks one question to reveal how serious drugmakers are about using technology | Advertisement
Corey McCann is the CEO of Pear Therapeutics, a company developing prescription digital therapeutics for conditions like substance use disorder and multiple sclerosis.
As pharmaceutical companies have increasingly become inter... |
| 10.12.2019 | US biosimilar launches about to turn a corner | The US biosimilar industry has lingered in the shadow of the European market since the US pathway for approvals was initiated in 2009.
Ten years later (or less than five years since the first FDA approval of a biosimilar),... |
| 16.10.2019 | Under new leadership, Novartis' Sandoz unit breaks up with digital therapeutics outfit Pear | Looks like Novartis’ Sandoz unit — under new leadership — has severed ties with Pear Therapeutics, dissolving the partnership that was inked in 2018.
Last year, Sandoz and Pear collaborated on and launched reSET, an FDA-... |
| 24.09.2019 | Novartis expands recall of heartburn meds to U.S. after finding carcinogen | After running tests, the Sandoz unit of Novartis (NVS) has expanded its recall of heartburn medicines containing ranitidine and is now pulling the products from the U.S.
The move comes one week after the drug maker halted worldwide distribu... |
| 24.10.2018 | Spend Your Fall Fridays at Smorgasburg & VICE's New Night Market | Some of the best food in New York City is available not at a white-tablecloth restaurant (what is this, the '80s?) or even the scene-y spot with exposed brick and two-hour wait, but rather served out of tents every weekend at Smorgasburg. T... |
| 15.10.2018 | German pharmaceutical Sandoz launches second Healthcare Access Challenge | German pharmaceutical company Sandoz has announced the launch of the second edition of its Sandoz Healthcare Access Challenge.
The Sandoz Hack is a global competition that invites entrepreneurs and innovators to submit ideas that can compl... |
| 15.10.2018 | German pharmaceutical Sandoz launches second Healthcare Access Challenge | German pharmaceutical company Sandoz has announced the launch of the second edition of its Sandoz Healthcare Access Challenge.
The Sandoz Hack is a global competition that invites entrepreneurs and innovators to submit ideas that can comple... |
| 19.04.2018 | Tocagen licenses immunotherapy to ApolloBio for $16M upfront; WuXi AppTec unveils expanded lab testing site in New Jersey | → San Diego-based Tocagen $TOCA has inked a licensing deal with ApolloBio, giving an affiliate of the Beijing-based company an exclusive license to develop and commercialize its cancer-selective immunotherapy. Toc... |
| 19.07.2016 | Novartis’ campaign to sweep biosimilar approvals hits a setback | Just as Novartis was leading the charge to open the floodgates on a wave of new biosimilar approvals, it hit a setback in the copycat wars. The pharma giant noted in its typically back-door fashion this morning that the FDA... |
| 20.06.2016 | Novartis takes aim at a slate of blockbusters with cheaper biosimilars | Novartis stepped in as one of the early pioneers in developing new biosimilars. And now the Swiss pharma giant has outlined its game plan to run the table with 5 new launches that will take aim at a slate of biologics that... |
| 01.11.2014 | Boulder County area’s largest employers in the private sector | 1.) IBM Corp.
Address: 6300 Diagonal Highway, Boulder, 80301
Phone: 303-924-6300
Website: ibm.com
Stock exchange/symbol: NYSE/IBM
Full-time employees in Boulder County region: 2,800 (estimate)
Part-time employees in Boulder County region: N... |
| 08.02.2012 | Success or withdrawal hang in balance for Shire blood pressure drug | Although the Irish pharmaceutical company, which has U.S. headquarters in the Philadelphia area, no longer manufactures the drug, it agreed to do the additional tests because it holds the new drug application for ProAmatine and did not want... |
| 11.01.2012 | CRO AAIPharma hires Patheon executive to be new CFO | “(Evans’) familiarity with our clients’ contract pharmaceutical manufacturing and development needs will help AAIPharma continue to execute our market expansion strategy and capitalize on compelling industry growth trends,” AAIPharma CEO Pa... |
| 10.01.2012 | iBio seeks to raise $10 million for plant-based vaccine production | Among the company’s pipeline of vaccines and biotherapeutics are vaccines for H1N1 influenza, or swine flu, in phase 1 clinical trials and human papillomavirus, or HPV, as well as plasma-derived proteins and monoclanal antibodies, both at t... |
| 08.12.2011 | Novartis gets FDA warning letter for N.C., Colorado and Quebec plants | Novartis, headquartered in Basel, Switzerland, has had at least three years notice for some of the problems. Many of the violations were first raised in a 2008 warning letter regarding the company’s Wilson, North Carolina plant. In the new ... |
| 05.12.2011 | Shire agrees to more clinical trials for blood pressure drug, but threat of FDA action lingers | Shire had resisted repeated requests for additional testing, arguing it had satisfied the testing requirements in 2005, but the FDA said it has not verified the clinical benefits of the drug. A letter sent to Shire in May 2001 said the comp... |
| 26.04.2011 | Inspire’s pink eye drug AzaSite draws generic challenge | Inspire in 2007 was granted a license to InSite’s patents, as well as a sublicense to Pfizer’s patents. InSite and Pfizer each have primary responsibility for enforcing rights of their respective patents. But the agreement did give Inspire ... |
| - | iBio seeks to raise $10 million for plant-based vaccine production | iBio (NYSE:IBIO) is seeking to raise $10 million for its plant-based vaccine production in a public offering.
The Newark, Delaware-based pharmaceutical company has priced 15,385,000 units at 65 cents per unit. Each unit includes one share o... |
| - | Inspire’s pink eye drug AzaSite draws generic challenge | Pink eye drug AzaSite, a major component of Inspire Pharmaceutical‘s (NASDAQ:ISPH) portfolio and one of the key products sought by Merck (NYSE:MRK) in its $430 million acquisition of the North Carolina company, could soon be facing generic ... |
| - | Shire agrees to more clinical trials for blood pressure drug, but threat of FDA action lingers | One year after Shire (NASDAQ:SHPGY) pulled its drug for low blood pressure, ProAmatine, from the market after reaching an impasse with the U.S. Food and Drug Administration, it has agreed to do the additional clinical tests the regulator wa... |
| - | Success or withdrawal hang in balance for Shire blood pressure drug | Shire (NASDAQ:SHPGY) has reached an agreement with U.S. regulators in the long-running saga over its low blood pressure drug, ProAmatine, that rests on the drug generating positive results in two clinical trials, or else face a withdrawal o... |
| - | A day in the life of a pre-tagged medication: Identifying risk within the medication use cycle | The journey a medication takes through the hospital is far more complex than most people would assume. From sourcing medication to ordering it, to organizing it within the hospital pharmacy and ensuring it gets to the right patient, there a... |
| - | CRO AAIPharma hires Patheon executive to be new CFO | Clinical research organization AAIPharma Services has hired its new CFO from the executive ranks of another pharmaceutical outsourcing services company.
Eric Evans joins the CRO from Patheon (TSX:PTI), a contract drug manufacturer based in ... |
| - | In FDA authorization of malaria drugs for Covid-19, some see politics at play | Buildings 1 and 2 of the FDA campus
Last weekend, the Food and Drug Administration granted an emergency use authorization for hydroxychloroquine and chloroquine to treat Covid-19, despite a paucity of data to support their use in the diseas... |
| - | Novartis gets FDA warning letter for N.C., Colorado and Quebec plants | The U.S. Food and Drug Administration is taking Novartis (NYSE:NVS) CEO Joseph Jimenez to task with a warning letter that cites three of the company’s manufacturing facilities for “significant violations” at the company’s generics drug unit... |
